Disposition and urinary excretion of vecuronium bromide in anesthetized patients with normal renal function or renal failure.
The effect and plasma concentrations of vecuronium bromide were measured in normal patients after an intravenous dose of 50, 100, or 150 micrograms/kg and in patients with renal failure after 50 or 100 micrograms/kg. Urinary excretion of vecuronium was studied in normal patients after the 150 micrograms/kg dose. Pharmacokinetic parameters of patients with or without renal failure were similar. No metabolites of vecuronium were found in the plasma. Twenty percent of vecuronium was excreted unchanged in the urine; 5% as the 3-hydroxy derivative. No other metabolites of vecuronium were found in the urine. Increasing doses of vecuronium shortened the onset, but prolonged the duration of action and the recovery rate, to a similar extent in patients with or without renal failure. It was concluded that the disposition of vecuronium was best described by a three compartment model. Both the disposition and the effect of vecuronium are only marginally disturbed by renal failure.
Bencini
A F
AF
Scaf
A H
AH
Sohn
Y J
YJ
Meistelman
C
C
Lienhart
A
A
Kersten
U W
UW
Schwarz
S
S
Agoston
S
S
D000328:Adult; D000768:Anesthesia, General; D005260:Female; D006801:Humans; D007668:Kidney / Q000378:metabolism; D007674:Kidney Diseases / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D009466:Neuromuscular Blocking Agents / Q000378:metabolism*; D010197:Pancuronium / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D014673:Vecuronium Bromide
D009466:Neuromuscular Blocking Agents; D014673:Vecuronium Bromide; D010197:Pancuronium